ライフサイエンスコーパス: did not differ significantly between

1 tal bacteria and individual species counts in dental plaque did not differ significantly between baseline and 3 months in

2 The SIR for CRC also did not differ significantly between first-degree relatives o

3 -forming units per mL), the number of vaccine serotype UTIs did not differ significantly between groups (0.046 mean episo

4 Results from the SDQ did not differ significantly between groups (P = .78).

5 ence 0.3%, 95% CI -0.8 to 1.5; p=0.566) and neonatal deaths did not differ significantly between groups (six [2.0%] vs th

6 Serotonin transporter binding in the cortex did not differ significantly between groups after age adjustm

7 The change in HbA1c levels from baseline did not differ significantly between groups at 3 months (adju

8 Most importantly, while the twofold clustering did not differ significantly between groups, blocking D2Rs si

9 absolute difference, -0.6%; 95% CI, -1.8% to 0.6%; P = .51) did not differ significantly between groups.

10 n, and serious adverse events, as well as 28-day mortality, did not differ significantly between groups.

11 tes of complete remission and the composite renal end point did not differ significantly between groups.

12 f small-for-gestational-age births and low Apgar score (<7) did not differ significantly between groups.

13 ants with the 72 unfunded grants, the overall success rates did not differ significantly between male (33.3%) and female

14 The mean values of D, D*, and Fp did not differ significantly between metastatic and non-metas

15 The UAS7/UAS7TD ratio was 0.96 +/- 0.21 and did not differ significantly between mild, moderate, and seve

16 Cortical thickness did not differ significantly between multiple sclerosis subje

17 Risk did not differ significantly between participants with zero a

18 Self-reported depression symptoms did not differ significantly between patients given CBT and t

19 INTERPRETATION: Change in 6MWD did not differ significantly between patients in the ataluren

20 In the IC2/3 population (n=234), overall survival did not differ significantly between patients in the atezoliz

21 Serious adverse events were documented and did not differ significantly between patients receiving PaCE

22 sease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received ex

23 Times of disease-free survival and overall survival did not differ significantly between patients with PDACs with

24 related to levels of intraluminal gas, but peak gas levels did not differ significantly between responders, nonresponder

25 with low SYNTAX scores (</=22), major cardiovascular events did not differ significantly between revascularization and me

26 Ten-year regional recurrence did not differ significantly between the 2 groups.

27 Mean daily energy intakes did not differ significantly between the 3 groups.

28 The primary endpoint did not differ significantly between the ASV and control grou

29 All-cause mortality did not differ significantly between the canakinumab and plac

30 The distribution of CGRP-positive nerves did not differ significantly between the distal esophageal mu

31 The proportions of skeletal-related events did not differ significantly between the every 4-week dosing

32 ion, the change in VABS-II score from baseline to 12 months did not differ significantly between the groups (P=0.70).

33 ould be evaluated, the rate of the primary efficacy outcome did not differ significantly between the hypothermia group an

34 Nine-week response rates did not differ significantly between the lithium and divalpro

35 ntion-to-treat analysis, the median number of ICU-free days did not differ significantly between the lower-target group a

36 0.91; P=0.04), but the incidence of silent brain infarction did not differ significantly between the study groups (P=0.97

37 Overall survival at 4 years did not differ significantly between the transplantation grou

38 -free survival than RVD therapy alone, but overall survival did not differ significantly between the two approaches.

39 r of days alive without delirium and without coma at day 14 did not differ significantly between the two groups (5.7 days

40 The rate of symptomatic intracranial hemorrhage did not differ significantly between the two groups (6% in th

41 but maternal and perinatal mortality and maternal morbidity did not differ significantly between the two groups.

42 er, medullary thyroid carcinoma, and serious adverse events did not differ significantly between the two groups.

43 T and creatine kinase, and the rates of bleeding and stroke did not differ significantly between the two groups.

44 f attempts, and the incidence of traumatic tap and backache did not differ significantly between the two needle groups.

45 tration of the released MalaEx harvested after 48 h culture did not differ significantly between the two pH conditions no

46 Sleep quality improved in both groups and did not differ significantly between them.

47 Spontaneous activity and energy expenditure did not differ significantly between treated and untreated mi

48 Time to infection also did not differ significantly between treatment arms.

49 Pancreas graft survival at 1 year did not differ significantly between volume categories: 86%,

50 l for gestational age, stillbirth, and congenital anomalies did not differ significantly between women who were taking AR